BRain Energy Activation With Ketones to Prevent Alzheimer's Disease - Trial NCT04466735
Access comprehensive clinical trial information for NCT04466735 through Pure Global AI's free database. This Phase 2 trial is sponsored by Université de Sherbrooke and is currently Recruiting. The study focuses on MCI. Target enrollment is 56 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Université de Sherbrooke
Timeline & Enrollment
Phase 2
Oct 15, 2020
Jul 01, 2023
Primary Outcome
Acetoacetate brain uptake,Glucose brain uptake
Summary
A six month randomized controlled intervention with an exogenous ketone salt (EKS) supplement
 in mild cognitive impairment. Participants will receive 15 g of the supplement twice daily
 (equivalent to 24 g/day of EKS). Outcomes: brain energy metabolism, cognition, plasma
 biomarkers, brain imaging (volumetric, functional, structural) and quality of life will be
 analyzed before and after the intervention.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT04466735
Non-Device Trial